Introduction {#sec1-1}
============

Myocardial remodeling is caused by a complex series of molecular and cellular mechanisms (Colucci, 1997), that result in an increase in cardiomyocyte diameter via broadening or linear expansion accompanied by cardiomyocyte necrosis and apoptosis (Ding et al., 2009).

Recently, many studies have demonstrated an association between the plasma vitamin D level and the occurrence of cardiovascular disease (Muscogiuri et al., 2016, Pilz et al., 2016). Vitamin D deficiency can result in activation of the renin-angiotensin-aldosterone system (RAAS)(Ferder et al., 2013). Vitamin D receptor (VDR) knockout mice and 1α-hydroxylase knockout mice showed individual myocyte enlargement and an elevation in natriuretic peptide expression (Glenn et al., 2016). Additionally, the renin expression level is increased in systemic and cardiac RAAS activation (Xiang et al., 2005, Zhou et al., 2008). Renin mRNA and protein expression is increased in the kidneys, and the cardiomyocytes appear hypertrophy and apoptosis(Bae et al., 2013). Active vitamin D acts on the VDR to interfere with the function of the renin promoter and inhibit renin gene transcription activation. Thus, vitamin D can inhibit the expression of the renin gene to regulate the RAAS (Nakane et al., 2007, Li et al., 2002). Additionally, vitamin D not only inhibits the generation of proinflammatory cytokines, such as interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α), but also increases the expression of anti-inflammatory cytokines, such as interleukin 10 (IL-10) (Barker et al., 2014, Liu et al., 2011). Vitamin D also has antioxidant effects (Lee et al., 2015) that improve myocardial metabolism, protect the mitochondria (Mukherjee et al., 1981), and inhibit apoptosis to protect the myocardium (Yao et al., 2015).

*Astragalus membranaceus* is a commonly used traditional Chinese herb that contains flavonoids, saponins, and other active ingredients that have wide pharmacological actions, including anti-diabetic, anti-hypertensive, anti-inflammatory, and cardioprotective effects as well as the prevention of heart failure(Huang et al., 2016, Li et al., 2017).*Astragaloside* (AST) is one of the main components of *Astragalus membranaceus* which could modulate the RAAS and inhibit cardiomyocyte hypertrophy and apoptosis to protect the heart (Shi et al., 2009, Zhang et al., 2015).

Using the Arrowsmith method (<http://arrowsmith.psych.uic.edu/cgi-bin/arrowsmith_uic/start.cgi>) , we found a correlation between *Astragalus* and vitamin D in the treatment of myocardial hypertrophy. Given this background, we hypothesized that the vitamin D axis played a vital role in the mechanism of *astragaloside* in treatment of cardiomyocyte hypertrophy. The present investigation was designed to study whether *astragaloside* exerted its anti-hypertrophic actions through the vitamin D axis.

Materials and Methods {#sec1-2}
=====================

Primary culture of rat cardiomyocytes {#sec2-1}
-------------------------------------

One-to-three-day-old newborn Sprague Dawley rats were purchased from the Animal enter of the Third Military Medical University (Chongqing, China). The ventricular myocardium was prepared as described previously (Menaouar et al., 2014). Briefly, the ventricular myocardium was excised, cut into small pieces, and washed three times with cold phosphate-buffered saline (PBS, ZSGB-BIO, China). Then, the tissues were digested 6 times for each 5 min at 37°C with 0.125% (w/v) trypsin (Beyotime, China). An equal volume of cold Dulbecco's modified Eagle's medium: Nutrient Mixture F-12 (DMEM/F12) (Gibco, USA) containing 10% (v/v) fetal bovine serum (FBS, Gibco, USA) was added to terminate the digestion. The cells were collected and centrifuged for 10 min at 1000 rpm at room temperature. Then, the cells were collected and suspended in DMEM/F12 complete medium containing 1% antibiotics (penicillin/streptomycin, Gibco, USA) and 10% (v/v) FBS and cultured in an incubator at 37°C with 5% CO~2~ and saturated humidity. The culture medium was renewed after 48 h, and the cells were cultured for an additional 24 h. Then, the medium was changed to serum-free DMEM/F12, and the cardiomyocytes were randomly divided into 6 groups as follows: 1. Control group (PBS); 2. ET-1 (10^-8^ mol/L, Sigma, USA) pretreatment group; 3. VD group (ET-1, 10^-8^ mol/L + Vitamin D,10^-8^ mol/L, Sigma, USA); 4. AST (10μg/mL) group (ET-1, 10^-8^ mol/L + AST, 10μg/mL, Sigma, USA); 5. AST (20μg/mL) group (ET-1, 10^-8^ mol/L+AST, 20μg/mL, Sigma, USA); and 6. AST (40μg/mL) group (ET-1,10^-8^mol/L+AST,40μg/mL, Sigma, USA). The experiments were performed after 24 h of treatment with the indicated drugs.

Immunohistochemistry {#sec2-2}
--------------------

The cell density was adjusted to 2×10^4^ cells/mL, and the cells were cultured on a cover glass. Then, the cover glass was fixed with 4% paraformaldehyde, cleared with PBS containing 0.5% Triton X-100, treated with 3% hydrogen peroxide (H~2~O~2~) in methanol to quench endogenous peroxidase activity, and blocked in 6% goat serum. The samples were incubated overnight with an α-actin antibody (Abcam, USA; diluted1:200) at 4°C. Then, the samples were incubated with a biotinylated secondary antibody (Abcam, USA; diluted 1:200) at 37°C for 30 min. HRP-labeled streptavidin and the HRP substrate were added, and the samples were incubated at 37°C for 30 min. A 3,3'-diaminobenzidine (DAB) (ZSGB-BIO, China) substrate system was used for color development in the dark. After counterstaining with hematoxylin, the sections were dehydrated for 5 min, dehydrated with an alcohol gradient, cleared with xylene, and mounted with neutral mounting medium.

Quantitative real-time polymerase chain reaction (qRT-PCR) {#sec2-3}
----------------------------------------------------------

The cells were digested and collected. RNA extraction was performed using the TRIzol reagent (Qiagen) according to the manufacturer's recommendations. Reverse transcription (RT) was conducted with random primers, and qRT-PCR was performed to examine the VDR, vitamin D 27-hydroxylase (CYP27B), vitamin D 24-hydroxylase (CYP24A) and renin mRNA expression levels; the primer sequences are listed in [Table 1](#T1){ref-type="table"}. The qRT-PCR amplification conditions were as follows: 94°C for 4 min, followed by 35 cycles of 94°C for 20 sec, 60°C for 30 sec, and 72°C for 30 sec. The analysis was repeated three times for each sample.

###### 

Primers and fluorescent probes used in the fluorescent quantitative PCR systems

  Name of the primer   Sequence (5'-3')          Amplified length (bp)
  -------------------- ------------------------- -----------------------
  VDR F                CCCGACCCTGGTGACTTTG       188
  VDR R                CGGTTGTCCTTGGTGATGC       
  CYP27B F             AGTGTTGAGATTGTACCCTGTGG   126
  CYP27B R             TCCCTTGAAGTGGCATAGTGA     
  CYP24 F              ACCAAAGTGTGGCAGGCAC       168
  CYP24 R              GACAGCGGCGTACAGTTCC       
  Renin F              CTGCTCAGGCTGTTGATGGA      168
  Renin R              AGTGAAAGTTGCCCTGGTAATG    
  Actin F              CCCATCTATGAGGGTTACGC      150
  Actin R              TTTAATGTCACGCACGATTTC     

Transmission electron microscope {#sec2-4}
--------------------------------

The cells were collected and fixed with glutaraldehyde/osmium tetroxide fixative. The samples were cut into a series of semi-thin sections and embedded. The sections were stained with compound dye (0.25% sodium borate: 0.25% basic fuchsin, 1:1) and cut into ultrathin sections after observation using a microscope. The ultrathin sections were put on a copper wire mesh and attached with a film prepared using a 0.45% Fonnvar solution. Then, the samples were dried on filter paper, stained with uranyl acetate and lead citrate, and examined using a transmission electron microscope (Royal Philips Tecnai-10, the Netherlands).

Flow cytometry {#sec2-5}
--------------

The cells were harvested by enzymatic digestion and washed in PBS. A total of 3×10^5^ cells were collected. The cells were incubated with 50 μL of 7-AAD staining solution (BD) at room temperature for 10 min in the dark. The solution was then centrifuged, the supernatant was discarded, and the cells were resuspended in 450 μL of binding buffer. The solution was incubated at room temperature for 10 min in the dark after the addition of 1 μL of Annexin V-PE staining solution. Cell apoptosis was analyzed by flow cytometry (BD Influx flow cytometer, USA) after cooling the solution in an ice bath. The BD FACSTM software was used to store and retrieve the data.

Statistical {#sec2-6}
-----------

Statistical analysis of the experimental data was performed using the SPSS software 17.0 (SPSS, Chicago, IL, USA). Measurement data were presented as the mean± standard deviation to compare the means of two variables (not groups) for the survey data. One-way ANOVA was used to compare differences among groups. A p-value\<0.05 was considered significant.

Result {#sec1-3}
======

Identification of rat cardiomyocytes {#sec2-7}
------------------------------------

During the initial inoculation period, the primary cardiomyocytes were transparent and round. The cells adhered to the culture dish approximately 24 h after inoculation. Non-adherent cells and impurities were eliminated with time and medium changes. After adherence, the cells began to spread and divide. The cells were fusiform or polygonal in shape with the nucleus located in the center of the cell. Cardiomyocytes were identified by immunohistochemical staining for rat α-actin ([Fig. 1](#F1){ref-type="fig"}).

![Identification of primary cardiomyocytes of rats](AJTCAM-14-278-g001){#F1}

Quantitative real-time polymerase chain reaction (qRT-PCR) {#sec2-8}
----------------------------------------------------------

The VDR, CYP24A, CYP27B and renin mRNA expression levels were evaluated by qRT-PCR. For each gene, the primer sets amplified a unique PCR product with a single-peak dissociation curve. The amplification efficiency of the PCR reactions was higher than 95%. *Relative quantification* of the PCR results *indicated that* the VDR and CYP27B mRNA expression levels were significantly reduced in the ET-1 group compared with the control group, whereas the CYP24A and renin mRNA expression levels were significantly increased in the ET-1 group (P\<0.05). The mRNA levels of all genes in VD group were similar to the expression levels in the control group (P\>0.05). AST groups had an effect similar to VD group. Thus, *astragaloside* and vitamin D may partially counteract the effects of ET-1 on the mRNA levels of the candidate genes in a dose-dependent manner ([Fig. 2](#F2){ref-type="fig"}).

![ET-1-induced cardiomyocyte hypertrophy was attenuated by AST in neonatal rat cardiomyocytes. (A--D) The mRNA expression levels of VDR, CYP27B, CYP24 and renin were evaluated by qRT-PCR analysis in cardiomyocytes exposed to control (PBS), ET-1 (10^-8^mol/L), VD and AST (10-40μg/mL). The data are expressed as the mean±sd. \**p*\<0.05, \*\**p*\<0.01 versus controls, \#*p*\<0.05, and \#\#*p*\<0.01 versus the ET-1 group.](AJTCAM-14-278-g002){#F2}

Cardiomyocyte hypertrophy {#sec2-9}
-------------------------

Ultrathin sections of the cells in each group were observed by TEM ([Fig. 4](#F3 F4){ref-type="fig"}). The observed ultrastructures revealed that the cardiomyocytes in the control group had a uniform nucleoplasm and smooth nuclear membranes. The mitochondrial cristae in the cardiomyocytes were arranged in an orderly and dense manner. After treatment with ET-1, the cells exhibited marginalized and aggregated chromatin and crinkled and distorted nuclear membranes; we also observed dense bodies in the cytoplasm. The cristae of the mitochondria were disordered, loose, and broken. When ET-1 and vitamin D were co-administered, the cells resembled the control group cells. When ET-1 and AST were co-administered, the area of the nuclei increased. The pathological changes in the mitochondria of the rat cardiomyocytes improved, and the chromatin aggregated in the middle of the nuclei ([Fig. 3](#F3){ref-type="fig"}).

![*Astragaloside* effect on mice cardiomyocyte. Transmission electron microscope. (A-F show group Ctrl, ET-1, VD, AST(10-40ug/ml))](AJTCAM-14-278-g003){#F3}

![Effect of AST on ET-1-induced cell apoptosis.(A-F show group Ctrl, ET-1, VD, AST(10-40ug/ml)). Figure G shows the rate of cardiomyocyte apoptosis. Data are expressed as means ± sd. \**p* \< 0.05, \*\**p* \< 0.01 versus control, \#*p* \< 0.05, \#\#*p* \< 0.01 versus ET-1 group.](AJTCAM-14-278-g004){#F4}

Flow cytometry {#sec2-10}
--------------

To examine the effect of AST on ET-1-induced cell death, apoptosis was examined by flow cytometry. The flow cytometry results indicated that the cell apoptosis rates in the control group, ET-1 group, ET-1 +VD group and ET-1 + AST group were 7.45±0.13%, 14.41±0.11%, 8.3±0.44%, 13.35±0.27%, 9.77±0.07% and 8.21±0.07%, respectively. A significant difference was observed in the survival rate between the control group and each experimental group (P\<0.01) ([Fig. 4](#F4){ref-type="fig"}).

Discussion {#sec1-4}
==========

Cardiomyocyte hypertrophy is an adaptive response to a variety of cardiovascular stimuli, such as the hemodynamic load (Devereux et al., 1983), growth factors(Karpanen et al., 2008) and hormones(Hu et al., 2005). Chronic cardiomyocyte hypertrophy may lead to cardiac arrhythmia (Ehses et al., 2000), myocardial infarction, heart failure, and even death; therefore, cardiomyocyte hypertrophy is considered an independent risk factor for an increase in cardiovascular morbidity and mortality(Mahdy Ali et al., 2012).

Renin is a rate-limiting step in angiotensin II (Ang II) production. Renin not only initiates the RAAS chain reaction with angiotensinogen (Yoshida et al., 2014), but also activates the prorenin receptor-activated intracellular signal transduction pathway, which is dependent on Ang II production. Thus, renin plays a vital role in promoting inflammation and proliferation, leading to cardiomyocyte hypertrophy and hyperplasia(Saris et al., 2006). A large number of studies have confirmed that activated RAAS regulates cardiomyocyte growth and apoptosis by endocrine and paracrine effects (Weir and Dzau, 1999)and that activate proinflammatory cytokines and exacerbate the inflammatory response (Sciarretta et al., 2009). Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs) play important roles in the treatment of chronic heart failure and coronary artery disease (Cohn, 2007, Bavry et al., 2014). However, these drugs failed to elicit the desired results (Lother and Hein, 2016). Currently, an emerging field is seeking to directly regulate the synthesis and release of renin through endogenous metabolic intermediates that block RAAS from the source. Vitamin D and it's analogues may be novel drugs for the prevention and treatment of chronic cardiovascular disease via the inhibition of the secretion of renin and the systemic and local RAAS(Pourdjabbar et al., 2013).

*Astragaloside* has wide pharmacological actions, including anti-diabetes, anti-hypertension, anti-inflammation (Xie and Du, 2011, Wang et al., 2016), cardiomyocyte protection, and anti-heart failure (Luo et al., 1995). *Astragaloside* regulates cardiomyocytes mainly by inducing NO release, preventing lipid peroxidation (Wang et al., 2015), eliminating oxygen free radicals, reducing oxidative damage in the body, improving the vigor of the myocardial sarcoplasmic reticulum Ca^2+^-ATPase (SERCA), stabilizing the intracellular Ca^2+^ concentration, inhibiting the overload of intracellular calcium(Meng et al., 2005, Lu et al., 1999), reducing cell damage, activating mitochondrial apoptotic pathways, and inhibiting cell apoptosis (Guan et al., 2015). Regulating the excessive activation of the RAAS and cytokine production may represent major roles in the inhibition of cardiomyocyte hypertrophy (Shi et al., 2009, Yang et al., 2013).

The preliminary results of the present study indicated that *astragaloside* inhibited ET-1-induced cardiomyocyte hypertrophy. The flow cytometry results showed that ET-1 induced apoptosis in cardiomyocytes and that *astragaloside* and vitamin D significantly ameliorated ET-1-induced cardiomyocyte apoptosis. *Astragaloside* influenced the VDR, CYP27B, and CYP24A mRNA expression levels in a dose-dependent manner. This result suggests that *astragaloside* treatment may reverse cardiomyocyte hypertrophy by regulating the levels of relevant factors in the vitamin D axis.

In summary, our study demonstrated that *astragaloside* was cardioprotective in cultured cardiomyocytes and exerted significant anti-hypertrophic activities at least partially through the vitamin D axis. These findings suggest that uncovering the mechanisms of *astragaloside* are important for the treatment of cardiovascular disease. Therefore, further in-depth investigations on *astragaloside* for cardiomyocyte hypertrophy are needed, especially at the molecular level, to provide a safer and more reliable treatment modality for cardiovascular diseases.
